Skip to content

Augmented Reality Navigation Versus Traditional CT Guidance for Preoperative Localization of Pulmonary Nodules

Application of Intelligent Augmented Reality Glasses in Assisting the Localization of Small Pulmonary Nodules:A Prospective, Randomized, Controlled, Noninferiority Trial

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06335563
Enrollment
166
Registered
2024-03-28
Start date
2024-03-14
Completion date
2024-12-01
Last updated
2024-04-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pulmonary Nodule

Brief summary

This study aims to conduct a large-sample randomized controlled clinical trial, using traditional CT-guided thoracic puncture localization as a comparison, to explore the accuracy, safety and clinical advantages of Intelligent AR glasses in assisting preoperative localizing of small pulmonary nodules.

Detailed description

This study is an open-label prospective single-center non-inferiority randomized controlled clinical trial. Patients in the Pulmonary Hospital Affiliated to Tongji University who are scheduled to undergo percutaneous puncture localization of small pulmonary nodules are used as the research subjects. According to the entry and exit criteria Patients were included in the clinical trial, and the enrolled patients were randomly divided into the AR glasses-assisted puncture localizing group (experimental group) and the CT-guided conventional pulmonary nodule puncture localizing group (control group), aiming to evaluate the puncture of pulmonary nodules guided by Intelligent AR glasses. Non-inferiority of localization compared with conventional CT-guided pulmonary nodule puncture localization.

Interventions

PROCEDUREAR glasses-assisted pulmonary nodule puncture localization

Combined with placing positioning marks on the patient's body surface and tracing the needle entry point with the assistance of a CT scan gantry laser. Disinfect the area around the puncture needle point, and use 2% lidocaine for local infiltration anesthesia. The doctor wears augmented reality (AR) glasses, completes the connection between the AR glasses and the puncture target, and clicks on the puncture point plane through the puncture target needle tip. Calibrate the puncture position at any two points. After confirming that the patient has held his breath, quickly puncture the needle into the pleura and advance it to the planned puncture position according to the screen prompts. After the second CT scan is performed to confirm that the puncture needle is positioned at a reasonable position, the positioning hook wire is released and the puncture needle sheath is withdrawn.

PROCEDURECT-guided pulmonary nodule puncture localization

Positioning markers are placed on the patient's surface and the first CT scan is performed. The needle insertion point and needle insertion depth are designed based on the two-dimensional CT scan image and the positioning marks. The location of the needle entry point was traced with the laser assistance of the CT gantry. Disinfect and puncture around the needle point, and use 2% lidocaine for local infiltration anesthesia. According to the designed needle path angle, the needle is first inserted under the skin, and a second CT scan is performed to confirm that the extension line of the puncture needle is within the nodule range. Then the needle is inserted to the target depth, and the third CT scan is performed. After confirming that the puncture needle is positioned at a reasonable position, the positioning hook wire is released and the puncture needle sheath is withdrawn.

Sponsors

Shanghai Pulmonary Hospital, Shanghai, China
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Masking description

no masking

Intervention model description

AR glasses-assisted puncture localizing group versus CT-guided conventional pulmonary nodule puncture localizing group

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

1. Age 18-80, no gender limit; 2. Chest CT shows that the nodule involves the outer third of the lung and can be removed by wedge resection; 3. Chest CT (lung window mode), the maximum diameter of the nodule is ≤2 cm; 4. Physical condition score ECOG 0-2 points; 5. If you plan to undergo percutaneous puncture and localization of small pulmonary nodules, the puncture needle path will be determined by the attending physician; 6. Patients voluntarily participate and sign informed consent.

Exclusion criteria

1. The lesion is located in front of the scapula, and the needle path is blocked; 2. The distance between the center of the lesion and the top of the diaphragm is \< 3 cm; 3. The lesion is adjacent to the hilus or large blood vessels; 4. Pleural adhesions caused by a history of thoracotomy or pleural infection; 5. The patient voluntarily withdraws midway.

Design outcomes

Primary

MeasureTime frameDescription
Accuracy of puncture localization of pulmonary nodulesIntraoperativeQuantified as the shortest distance from the actual position of the puncture needle tip to the originally planned puncture point

Secondary

MeasureTime frameDescription
Success rate of puncture localization of pulmonary nodulesIntraoperativeThe puncture is defined as successful when the distance between the actual localizing point of the puncture needle tip and the center of the localized nodule does not exceed 20 mm.
Adjust the number of needle puncturesIntraoperativeNumber of needle insertion attempts required for successful localizing
Operating timeIntraoperativeThe time span from the patient's first CT scan to the last CT scan, in minutes
Radiation doseIntraoperativeThe length product value of the radiation dose recorded by the CT scanner, measured in mGy \* cm

Countries

China

Contacts

Primary ContactYunlang She, MD
sylxan3344@163.com+86 17749739242
Backup ContactDeping Zhao, MD, PhD
zdp1992@163.com+86 13701816883

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jul 30, 2026